Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

2026 M&A Outlook with 5 trends firms should track for 2026
Buyers have learned to normalise and move through uncertainty, supported by lower financing costs and increased confidence in future growth prospects.
The regulatory future for sole trustees
Last month the Association of Professional Pension Trustees (APPT) published its revised sole trustee code of practice, effective from 1 January 2026.
The Purple Book 2025 Webinar
In this exclusive webinar, Professional Pensions editor, Jonathan Stapleton, is joined by our Chief Actuary, Shalin Bhagwan, and our Actuary, James Em

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.